Complexa: Novel Treatment for Contrast-Induced Acute Kidney Injury
The Contrast Induced Kidney market is a large one, at about $500 million. This is due to the fact that Acute Kidney Injury affects 3-7% of all patients admitted into hospitals and about 25-30% of patients admitted into the Intensive Care Unit. Complexa’s technology has the potential to treat an issue many sick Americans face today.